Precirix

Burgemeester Etienne Demunterlaan 3

1090 Brussel (Jette)

BE

Precirix

Foundation date

14/10/2014

Sector

#Biotechnology - Therapeutics

Therapeutic areas

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

The company’s lead product, CAM-H2, is being evaluated in a Phase I/II trial targeting metastatic HER2-positive cancer. Patients with tumors that overexpress HER2 can benefit from effective targeted treatments today yet have a poor prognosis when the cancer spreads. CAM-H2 aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of sdAbs.

The company’s technology platform also allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-H2, the company has two product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.

Upcoming events

Latest news

  • Mithra reaches milestone in estetrol skin study

    Tuesday April 9th 2024

  • Stool transplant shows promise for Parkinson's disease

    Thursday April 4th 2024

  • Strong data from Sequana Medical's DSR® proof-of-concept studies in heart failure published in European Journal of Heart Failure

    Wednesday April 3rd 2024

Jobs by Precirix